Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) has been assigned a consensus recommendation of “Buy” from the twenty-four analysts that are presently covering the stock, MarketBeat reports. Four analysts have rated the stock with a hold rating and twenty have given a buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $182.49.
Several research analysts have recently weighed in on the company. Piper Jaffray Companies restated a “buy” rating and set a $201.00 target price on shares of Jazz Pharmaceuticals in a report on Thursday, March 1st. HC Wainwright set a $160.00 target price on Jazz Pharmaceuticals and gave the stock a “hold” rating in a report on Wednesday, May 9th. ValuEngine cut Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Seaport Global Securities set a $175.00 target price on Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, April 6th. Finally, Zacks Investment Research upgraded Jazz Pharmaceuticals from a “hold” rating to a “buy” rating and set a $189.00 target price on the stock in a report on Thursday, May 31st.
Shares of Jazz Pharmaceuticals stock traded up $1.42 on Friday, hitting $177.23. 406,435 shares of the company were exchanged, compared to its average volume of 471,219. The stock has a market cap of $10.68 billion, a P/E ratio of 18.54, a P/E/G ratio of 0.91 and a beta of 0.96. Jazz Pharmaceuticals has a 1-year low of $128.58 and a 1-year high of $179.19. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.00 and a quick ratio of 2.88.
In other Jazz Pharmaceuticals news, CFO Matthew P. Young sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, June 1st. The stock was sold at an average price of $170.04, for a total value of $850,200.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $150.01, for a total value of $150,010.00. Following the completion of the sale, the chief executive officer now directly owns 293,542 shares in the company, valued at approximately $44,034,235.42. The disclosure for this sale can be found here. In the last three months, insiders sold 24,179 shares of company stock worth $3,965,975. 4.30% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Suntrust Banks Inc. raised its position in Jazz Pharmaceuticals by 6.9% in the first quarter. Suntrust Banks Inc. now owns 12,068 shares of the specialty pharmaceutical company’s stock valued at $1,821,000 after purchasing an additional 775 shares during the period. Allianz Asset Management GmbH raised its position in Jazz Pharmaceuticals by 2.2% in the first quarter. Allianz Asset Management GmbH now owns 111,701 shares of the specialty pharmaceutical company’s stock valued at $16,865,000 after purchasing an additional 2,422 shares during the period. Summit Trail Advisors LLC raised its position in Jazz Pharmaceuticals by 8,591.5% in the first quarter. Summit Trail Advisors LLC now owns 102,125 shares of the specialty pharmaceutical company’s stock valued at $102,000 after purchasing an additional 100,950 shares during the period. CIBC World Markets Inc. purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at approximately $579,000. Finally, Xact Kapitalforvaltning AB raised its position in Jazz Pharmaceuticals by 2.6% in the first quarter. Xact Kapitalforvaltning AB now owns 14,606 shares of the specialty pharmaceutical company’s stock valued at $2,205,000 after purchasing an additional 374 shares during the period. 88.91% of the stock is currently owned by institutional investors.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.